- Poster presentation
- Open Access
Clinical features and prognosis of patients co-infected with HIV and tuberculosis in the ICU
© Pecego et al.; licensee BioMed Central Ltd. 2013
- Published: 5 November 2013
- Respiratory Failure
- Hospital Mortality
- Neurological Dysfunction
Despites advances in treatment, tuberculosis (TB) remains a global health threat and is the leading co-infection among Brazilian HIV-infected patients [1–4]. Mortality of TB in the presence of sepsis and shock septic can be as high as 67%, with respiratory failure being the leading cause of ICU admission [2, 3, 5]. Clinical factors that enhance mortality among HIV-TB patients are yet to be explored.
We retrospectively accessed data of HIV/AIDS critically ill patients from January 2007 until May 2012, at a referral infectious diseases hospital. All patients admitted to the ICU with laboratory-confirmed TB were included in the analysis. Demographic and clinical data were categorized for survivors and nonsurvivors and the results were displayed as frequency (%), median values and interquartile range.
Fifty patients were included. Hospital mortality was 48%. Age was 31.5 years (26.5 to 42.75) in the survivors group versus 33.5 years (30 to 45.25) in nonsurvivors (P = 0.25), and the SAPS II score was 44.5 (37.25 to 55.75) versus 47.25 (38.75 to 54.25) (P = 0.58). The most common TB presentation was disseminated disease (56%) followed by pulmonary (44%), with no difference according to survival. The delta of days between ICU admission and beginning of TB treatment was not different between groups. Rifampicin (94%), pyrazynamide (94%), isoniazide (92%) and ethambutol (76%) were administered in the majority of patients, while fluoroquinolones and aminoglycosides were administered in 64% and 54% respectively. Nonsurvivors presented with more elapsed time since HIV diagnosis (1 (1 to 7) vs. 26 (5 to 72), P = 0.10); lower nadir CD4 cell count (72.5 (27.5 to 133.5) vs. 24 (14.5 to 63), P = 0.03); and HAART initiated within 30 days after admission (62% vs. 29%, P = 0.03, odds ratio 3.9 (95% CI 1.2 to 12.7)). The main reason for ICU admission was respiratory failure (70%). Nonsurvivors needed mechanical ventilation (88% vs. 48%, P = 0.006) and vasopressors (71% vs. 41%, P = 0.05) more frequently. Neurological dysfunction was more common in nonsurvivors (79% vs. 41%, P = 0.01, odds ratio 5.2 (95% CI 1.5 to 18.2)). After multivariate analysis, neurological dysfunction was associated with higher mortality, while HAART in the first 30 days of hospitalization was a protective associated factor.
The disseminated form was the most common presentation of TB in HIV/AIDS critically ill patients. Nonsurvivors were more prone to multiple organ dysfunction syndrome, with neurological dysfunction associated with hospital mortality. The administration of HAART within 30 days of hospitalization was associated with survival.
- Pacheco AG, Duronvi B, Cavalcante SC: AIDS-related tuberculosis in Rio de Janeiro, Brazil. Plos One 2008, 3: 3132. 10.1371/journal.pone.0003132View ArticleGoogle Scholar
- Silva DR, Menegotto DM, Schulz LF, et al.: Mortalitity among patients with tuberculosis requiring intensive care: a retrospective cohort study. BMC Infect Dis 2010, 10: 54. 10.1186/1471-2334-10-54PubMed CentralView ArticlePubMedGoogle Scholar
- Zahar J-R, Azoulay E, Klement E, et al.: Delayed treatment contributes to mortality in ICU patient with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med 2001, 27: 513-520. 10.1007/s001340000849View ArticlePubMedGoogle Scholar
- Powell K, Huang L: The art of caring for patients with of HIV infection at the ICU. Intensive Care Med 2009, 35: 1659-1661. 10.1007/s00134-009-1578-1PubMed CentralView ArticlePubMedGoogle Scholar
- Japiassú AM, Amâncio RT, Mesquita EC, Medeiros D, Bernal HB, Nunes EP, Luz PM, Grinsztejn B, Bozza F: Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care 2010, 14: R152. 10.1186/cc9221PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.